Diabetes medications

Use of SGLT2 inhibitors rather than sulfonylureas as an addition to metformin therapy may be associated with a reduced mortality risk for people with type 2 diabetes, suggest real-world study findings.

Treatment with the SGLT2 inhibitor dapagliflozin produces acute increases in renal oxygenation in people with type 1 diabetes and albuminuria, say researchers.

Early achievement of a glycated hemoglobin (HbA1c) level below 7% is a key factor in maintaining long-term glucose control in people with type 2 diabetes initiating second-line glucose-lowering therapy, DISCOVER study data show.

Reasons for ethnic disparities in statin prescribing in UK residents with type 2 diabetes are not clear, but may result in preventable atherosclerotic cardiovascular disease events, research suggests.

Stefan Bornstein provides an overview of the current understanding about COVID-19 and diabetes, including medications, vaccines, and the impact of SARS-CoV-2 infection on diabetic ketoacidosis.

A 6-month course of treatment with the tyrosine kinase inhibitor imatinib may slow the decline in beta-cell function in people with newly diagnosed type 1 diabetes, but the effect is not sustained in the longer term, phase 2 study findings indicate.

Treatment with efpeglenatide significantly improves glycemic control and results in weight loss for medication-naïve people with type 2 diabetes, report the AMPLITUDE-M researchers.

Findings from the DISCOVER study indicate that global use of SGLT2 inhibitors and GLP-1 receptor agonists has increased over time among people with type 2 diabetes, but remains suboptimal.

People with type 2 diabetes who lose weight while taking semaglutide have a parallel improvement in their health-related quality of life, particularly that related to physical exertion, report the STEP 2 investigators,

Further analyses from STEP 2 show improvements in multiple cardiometabolic risk markers with semaglutide versus placebo, and potentially greater weight loss in women than men.

Taking semaglutide 2.4 mg can reduce the likelihood of people with overweight or obesity developing type 2 diabetes, shows further analysis of STEP 1.

Click through to read more on this announcement

Patrick Holmes discusses whether the GRADE study answers the question of which type 2 diabetes medication should be used after metformin, and comments on the generalizability of the findings.

The duration of statin therapy in people with type 2 diabetes may be even more important than the intensity or the achieved level of low-density lipoprotein cholesterol for preventing cardiovascular events, research suggests.